Guselkumab is an investigational human monoclonal antibody directed specifically against IL-23.
‘Real-world’ study data mirror that of earlier phase 3 trials.
Researchers are beginning to unravel the functional significance of key gene variants in psoriasis.
Evidence mixed on efficacy of low-calorie and gluten-free diets in reducing psoriasis symptoms.
Patients receiving combination therapy saw greater improvement in symptoms compared with patients receiving monotherapy.
Combination treatment avoids side effects often seen with systemic therapy.
Lifestyle modifications may support the pharmacologic treatment of obese psoriasis patients.